“We will continue to pursue legal action against those who provide potentially unsafe and ineffective compounded ‘semaglutide’ products and knowingly deceive patients who are seeking treatment, thereby eroding public trust in the safety of FDA-approved medicines,” said Doug Langa, executive vice president, North America operations and president of Novo Nordisk.


CEO of Speaker Media and Marketing, is the "Secret Weapon of Personal Injury Lawyers and Trial Attorneys" throughout the United States. Specializing as a marketing consultant to lawyers, with a primary focus on content marketing, social media, online video and mobile marketing strategies.